J.P. Morgan upgraded Biogen to Overweight with a $300 price target, citing upcoming clinical catalysts including felzartamab and litifilimab. Shares rose 3.7%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
